AstraZeneca has taken the number one spot in IDEA Pharma’s Pharmaceutical Innovation Index (PII) – an index which celebrates the most innovative companies in pharma.
IDEA Pharma have announced the 2018 rankings for their Pharmaceutical Innovation Index (PII), confirming that we had catapulted from 15th place in 2017 to the number one spot in 2018.
The PII, now in its eighth year, provides a systematic and objective assessment of how well the top 30 companies perform in successfully bringing new medicines to market and commercialising them.
The index utilises a range of clinical, regulatory and commercial metrics to do this, ranging from the corporate level down to individual products.
“A series of strategic and successful decisions that helped generate a substantial amount of robust positive data for their pipeline and began to stem the company’s downward trend since the loss of several product exclusivities between 2011 and 2017. AstraZeneca managed to launch five significant new medicines in 2017, across their primary therapy areas. In addition to these new drug approvals, AstraZeneca accumulated 14 other regulatory approvals across indication expansion and LCM projects in major markets. Over the past year AZ has also racked up 3 Breakthrough Therapy Designations (including 2 Orphan Drug Designations) and 6 additional Priority Review Designations.”
Summary from IDEA Pharma report authors, read more about the index here.
The time it takes to advance a therapy all the way through the regulatory process, from experimental molecule to market, is a key metric for the index and we were specifically recognised for two launches which received accelerated approval and our success and advancement of clinical trials.
Interested in joining AstraZeneca?
From scientists to sales, lab techs to legal, we’re on a mission to turn ideas into life-changing medicines that improve patients’ lives and benefit society. We need great people who share our passion for science and have the drive and determination to meet the unmet needs of patients around the world.
Please visit our Careers pages for more information